Effects of antiviral agents and HBV genotypes on intrahepatic covalently closed circular DNA in HBeAg-positive chronic hepatitis B patients

Table 3 Histological, biochemical and virological data on HBV genotypes C and B (mean ± SD)

Parameter	HBV Genotype C	HBV Genotype B
Number of patients	61	10
Sex ratio (male/female)	50/11	9/1
Number of Sequential therapy	20 (32.8%)	4 (40%)
Number of Lamivudine therapy	31 (50.8%)	4 (40%)
Number of Interferon therapy	10 (16.4%)	2 (20%)
Mean Knodell score
Pretreatment	8.1 ± 4.1	5.7 ± 3.2
Post-treatment	6.0 ± 3.4a	5.4 ± 3.1
Mean ALT level (nkat/L)
Pretreatment	3390 ± 2438	2438 ± 2296
Post-treatment	901 ± 918	551 ± 233
24 wk off-treatment	1503 ± 1336	1987 ± 1720
Serum HBV DNA (log10)
Pretreatment	7.7 ± 1.2	7.6 ± 0.8
Post-treatment	4.05 ± 1.3a	4.9 ± 1.2a
24 wk off-treatment	5.1 ± 1.6	5.3 ± 1.3
Intrahepatic HBV DNA (log10)
Pretreatment	6.1 ± 0.9	5.6 ± 1.5
Post-treatment	4.9 ± 1.4a	4.7 ± 1.2a
Intrahepatic ccc DNA (log10)
Pretreatment	5.6 ± 1.1	5.8 ± 0.5
Post-treatment	3.5 ± 1.2a	3.9 ± 1.9
Sustained virological response rate at
24 wk off-treatment	29.4% (15/51)	30% (3/10)
ALT normalization rate at
24 wk off-treatment	39.3% (24/51)	30% (3/10)

^aP < 0.05 vs post-treatment. ALT: Alanine aminotransferase; ccc DNA: Covalently closed circular DNA.